Period:
Draw Mode:
| Volume | 16,773 |
|
|||||
| News | - | ||||||
| Day High | 2.97 | Low High |
|||||
| Day Low | 2.71 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Sonnet BioTherapeutics Holdings Inc | SONN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.035 | 1.24% | 2.865 | 16:00:01 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.79 | 2.71 | 2.97 | 2.865 | 2.83 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 274 | 16,773 | $ 2.85 | $ 47,846 | - | 2.665 - 66.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:00 | 28 | $ 2.86 | USD |
Sonnet BioTherapeutics Holdings Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 5.02M | 1.75M | - | 350k | -29.72M | -16.98 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Sonnet BioTherapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SONN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.21 | 3.30 | 2.665 | 2.93 | 40,908 | -0.345 | -10.75% |
| 1 Month | 4.31 | 4.80 | 2.665 | 3.96 | 78,318 | -1.45 | -33.53% |
| 3 Months | 9.90 | 10.56 | 2.665 | 7.78 | 1,209,420 | -7.04 | -71.06% |
| 6 Months | 7.81 | 26.40 | 2.665 | 9.98 | 2,786,590 | -4.95 | -63.32% |
| 1 Year | 33.66 | 66.00 | 2.665 | 27.10 | 2,575,626 | -30.80 | -91.49% |
| 3 Years | 770.00 | 1,051.82 | 2.665 | 185.59 | 3,067,210 | -767.14 | -99.63% |
| 5 Years | 1,915.76 | 4,989.60 | 2.665 | 331.26 | 3,022,703 | -1,912.90 | -99.85% |
Sonnet BioTherapeutics Description
| Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others. |